Cochrane for Clinicians
Putting Evidence into Practice
Citrate Salts for Preventing and Treating Calcium-Containing Kidney Stones in Adults
Am Fam Physician. 2017 May 1;95(9):552-553.
Author disclosure: No relevant financial affiliations.
Do citrate salts treat and prevent calcium-containing kidney stones in adults?
Citrate supplementation reduces stone size to less than 5 mm and prevents new stone formation when compared with placebo or no intervention. Citrate therapy also stabilizes existing stones and decreases the need for retreatment. These benefits come at the expense of upper gastrointestinal disturbances that lead to a higher dropout rate.1 (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)
In the United States, the prevalence of symptomatic kidney stones is 8.8% in the general population, and is higher in men (10.6%) and obese individuals (11.2%).2 Without prevention, 10% of individuals will have a symptomatic recurrence of stones at one year, 33% at five years, 50% at 10 years, and 75% at 20 years.3 Urinary tract stones represent an important health care expense with charges exceeding $10 billion annually in the United States.3 Because citrate binds urinary calcium, it may inhibit the formation of calcium oxalate stones; therefore, the authors of this Cochrane review aimed to determine if the use of citrate salts can prevent and treat calcium-containing kidney stones.
This Cochrane review included seven randomized controlled trials with a total of 477 participants.1 Three studies compared potassium citrate supplementation with placebo or no intervention, and three studies compared potassium-sodium citrate with no intervention. One study compared potassium-magnesium citrate with placebo. Primary outcomes included radiographic evidence (plain radiography, computed tomography, or intravenous urography) of reduced stone size to less than 5 mm, lack of new stone formation, or stone size stability over six months, one year, or two years. Secondary outcomes were the need for retreatment, adverse events, and dropout rates. Dosages of citrate therapy ranged from 30 to 60 mEq per day.
Citrate therapy increased the likelihood of stone size reduction to less than 5 mm (relative risk [RR] = 2.35; 95% confidence interval [CI], 1.36 to 4.05). The incidence of new stone formation over a period of 12 to 48 months was also significantly reduced (RR = 0.26; 95% CI, 0.10 to 0.68). Citrate therapy prevented growth of existing stones (RR = 1.97; 95% CI, 1.19 to 3.26). Only two studies reported the need for retreatment as an outcome; in these, citrate therapy significantly decreased the need for retreatment vs. control (RR = 0.22; 95% CI, 0.06 to 0.89) over a follow-up period of three to four years. In absolute terms, the need for retreatment was 3.6% vs. 41.4% in the first study4 and 8% vs. 22% in the second.5
Adverse events and dropout rates were higher in the citrate treatment groups. The most commonly reported adverse events with citrate treatment were upper gastrointestinal disturbance and rash, but these differences were not significant between the citrate and placebo groups. Although rates of adverse events did not significantly differ between groups, dropout rates because of adverse events were significantly higher in patients receiving citrate therapy (RR = 4.45; 95% CI, 1.28 to 15.50). Overall, dropout rates because of noncompliance were similar between the groups. Risk of bias was considered low. The individual studies did not provide enough information for the authors of this review to reach a conclusion regarding the most effective dose of citrate salts.
Current guidelines from the American College of Physicians recommend that patients with one or more previous kidney stone episodes increase their fluid intake to produce at least 2 L of urine per day.6 If increased fluid intake fails to prevent recurrent episodes, treatment with a thiazide diuretic, allopurinol, or citrate is recommended. These recommendations are based on moderate-quality evidence.6 The results of this Cochrane review support the recommendations in the American College of Physicians guidelines.
The practice recommendations in this activity are available at http://www.cochrane.org/CD010057.
REFERENCESshow all references
1. Phillips R, Hanchanale VS, Myatt A, Somani B, Nabi G, Biyani CS. Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev. 2015;(10):CD010057....
2. Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160–165.
3. Scales CD Jr, Tasian GE, Schwaderer AL, Goldfarb DS, Star RA, Kirkali Z. Urinary stone disease: advancing knowledge, patient care, and population health. Clin J Am Soc Nephrol. 2016;11(7):1305–1312.
4. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol. 1993;150(6):1761–1764.
5. Jiménez Verdejo A, Arrabal Martín M, Miján Ortiz JL, Hita Rosino E, Palao Yago F, Zuluaga Gómez A. Effect of potassium citrate in the prophylaxis of urinary lithiasis [in Spanish]. Arch Esp Urol. 2001;54(9):1036–1046.
6. Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(9):659–667.
These are summaries of reviews from the Cochrane Library.
This series is coordinated by Corey D. Fogleman, MD, Assistant Medical Editor.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Apr 15, 2021
Access the latest issue of American Family Physician